4d Pharma PLC Annual Report and Notice of AGM (1456P)
05 Junio 2020 - 7:00AM
UK Regulatory
TIDMDDDD
RNS Number : 1456P
4d Pharma PLC
05 June 2020
4D pharma plc
(the "Company" or "4D")
Annual Report and Notice of AGM
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the
development of Live Biotherapeutics, announces that the Annual
Report and Accounts for the year to 31 December 2019 (the "Annual
Report") and the notice of the Company's Annual General Meeting
("Notice of AGM") have been posted to shareholders.
Electronic copies of both the Annual Report and the Notice of
AGM are now available on the Company's website, www.4dpharmaplc.com
.
The AGM will be held in at 9 Bond Court, Leeds, LS1 2JZ, at 10
a.m. on Tuesday, 30 June 2020.
As previously announced on 26 May, In light of the current
guidance from the UK Government which prevents public gatherings of
more than two people, shareholders, advisers and other guests will
not be allowed to attend the AGM and anyone seeking to attend the
meeting in person will be refused entry. We therefore encourage
shareholders to submit any questions they would like to pose to the
Board to ir@4dpharmaplc.com so as to be received no later than 26
June 2020. All emails should be marked "AGM Question" in the
subject line, and will require a shareholder number. If the UK
Government's guidance changes before the AGM and allows gatherings
of more than two people, we will notify you via the Company's
website at www.4dpharmaplc.com.
For further information please contact:
4D
Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130
Investor Relations ir@4dpharmaplc.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000
Aubrey Powell / Justin McKeegan / Alex Bond (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson / Phil Walker
About 4D
Founded in February 2014, 4D pharma is a world leader in the
development of Live Biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacterium, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform, MicroRx(R), that rationally identifies Live
Biotherapeutics based on a deep understanding of function and
mechanism.
4D's Live Biotherapeutic Products are orally delivered single
strains of bacteria that are naturally found in the healthy human
gut. The Company has five clinical studies in progress, namely a
Phase II clinical study of BLAUTIX(R) in Irritable Bowel Syndrome
(IBS), a Phase I/II study of MRx0518 in combination with
KEYTRUDA(R) (pembrolizumab) in solid tumours, a Phase I study of
MRx0518 in a neoadjuvant setting for patients with solid tumours, a
Phase I study of MRx0518 in patients with pancreatic cancer and a
Phase I/II study of MRx-4DP0004 in asthma. Preclinical-stage
programmes include candidates for CNS disease such as Parkinson's
disease and other neurodegenerative conditions. The Company has a
research collaboration with MSD, a tradename of Merck & Co.,
Inc., Kenilworth, NJ, USA, to discover and develop Live
Biotherapeutics for vaccines.
Further information is available at the 4D's website,
www.4dpharmaplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFLFSLREIEIII
(END) Dow Jones Newswires
June 05, 2020 08:00 ET (12:00 GMT)
4d Pharma (LSE:DDDD)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
4d Pharma (LSE:DDDD)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024